Risk for breakthrough infection and of 60-day hospitalization significantly lower for mRNA-1273 versus BNT162b2 vaccination<\/strong><\/p>\n<\/h3>\n <\/b><\/p>\n <\/b><\/p>\n WEDNESDAY, Feb. 2, 2022 (HealthDay News) — Recipients of mRNA-1273 versus BNT162b2 had a lower risk for breakthrough severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during predominance of the delta variant, according to a research letter published online Jan. 20 in the Journal of the American Medical Association<\/em>.<\/p>\n Lindsey Wang, from the Case Western Reserve University School of Medicine in Cleveland, and colleagues identified breakthrough SARS-CoV-2 infections that occurred between July and November 2021, when the delta variant predominated, in fully vaccinated individuals receiving two doses of an mRNA vaccine, who had not received a booster shot and had no previous infection (62,628 individuals in the mRNA-1273 cohort and 574,538 in the BNT162b2 cohort).<\/p>\n The researchers found that from July to November 2021, the monthly incidence of breakthrough infections increased in both cohorts and was higher in the BNT162b2 than the mRNA-1273 cohort, reaching 2.8 and 1.6 cases per 1,000 person-days, respectively, in November. Compared with the matched BNT162b2 cohort, the mRNA-1273 cohort had a significantly lower risk for breakthrough infections after matching (hazard ratio, 0.85). The 60-day hospitalization rate was 12.7 and 13.3 percent for mRNA-1273 and BNT162b2 recipients, respectively; 60-day mortality was 1.14 and 1.10 percent, respectively. Among the matched cohorts, the risk for 60-day hospitalizations was lower for mRNA-1273 versus BNT162b2 recipients (hazard ratio, 0.80). Mortality did not differ significantly between the cohorts.<\/p>\n “Although there is a difference in breakthrough infections, both vaccines are highly protective against SARS-CoV-2 infection and especially against the most severe consequences of infection,” a coauthor said in a statement.<\/p>\n